Author(s):
Srinivasa Reddy, Licto Thomas, Venkatesan P, Arindam Mukhopadhyay, Saral Thangam
Email(s):
Arindam.Mukhopadhyay@norwichclinical.com
DOI:
10.52711/2231-5675.2023.00003 
Address:
Srinivasa Reddy, Licto Thomas, Venkatesan P, Arindam Mukhopadhyay*, Saral Thangam
Norwich Clinical Services, Bangalore, Karnataka, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 1,
Year - 2023
ABSTRACT:
A LCMS/MS method for the simultaneous determination of ampicillin and sulbactam in human plasma was described. After protein precipitation using 2mL of acetonitrile, 250µL of supernatant was mixed with 1.000 mL of 0.1% Acetic Acid in Milli-Q-water. 10µL was injected to a Biobasic AX column and eluted with 10mM Ammonium acetate and Acetonitrile: 60:40, v/v at a flow rate of 0.5mL/min. MRM transitions were monitored in negative mode as m/z 348.1 ? 206.8 (AMP), 231.9 ? 187.8 (SUL) and m/z 353.0 ? 211.9 (AMP D5). Sample concentrations were calculated by linear regression analysis using the analyst software1.6.3. An excellent linear response was obtained over the concentration ranges 0.1040µg/mL to 10.1562µg/mL for Ampicillin and 0.0510µg/mL to 6.1552µg/mL for Sulbactam. The intra-day and inter-day precision were within 3.50% for all analytes. The assay accuracy was 96.27 –103.59 %. Mean recoveries were 84.51% and 98.54% for ampicillin and sulbactam, respectively. The limits of detections were 0.026µg/mL and 0.013µg/mL for ampicillin and sulbactam. This method was successfully used for a bioequivalence study.
Cite this article:
Srinivasa Reddy, Licto Thomas, Venkatesan P, Arindam Mukhopadhyay, Saral Thangam. Simultaneous Estimation of Ampicillin and Sulbactam in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry. Asian Journal of Pharmaceutical Analysis. 2023; 13(1):13-0. doi: 10.52711/2231-5675.2023.00003
Cite(Electronic):
Srinivasa Reddy, Licto Thomas, Venkatesan P, Arindam Mukhopadhyay, Saral Thangam. Simultaneous Estimation of Ampicillin and Sulbactam in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry. Asian Journal of Pharmaceutical Analysis. 2023; 13(1):13-0. doi: 10.52711/2231-5675.2023.00003 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2023-13-1-3
REFERENCES:
1. Jack Cazes, Encyclopedia of Chromatography, 2004, Updated supplement, Pages- 330.
2. Robert E. Andrey, Liquid Chromatography-Mass Spectrometry: An Introduction, Pages-7.
3. A.H. Buckett, J.B. Stenlake, Practical Pharmaceutical Chemistry, 4th edition, Part- II, Pages-165-166.
4. Monika Bakshi, Saranjit Singh, J. Pharmaceutical And Biomedical Analysis, Vol- 28, 2002, Page No. 1011.
5. Susan P. B, Febuxostat; A selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. The Annals of Pharmacotherapy. 2006; 40: 2187-2194.
6. Charnelda L.G, NafesaE, Walters-Smith. Febuxostat for treatment of chronic gout. American Journal of Health-System Pharmacy. 2011; 68(5): 389-398.
7. Ramallo I.A, Susana A.Z, Ricardo L.E.F. A rapid TLC autographic method for the detection of xanthine oxidase inhibitors and superoxide scavengers. Phytochemical Analysis, 2006; 17(1): 15-19.
8. Grabowski B. A, Khosravan R, Vernillet L, Mulford D. J, Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects, Journal of Clinical Pharmacology, 2011; 51(2): 2011.
9. Khosravan R., Grabowski B, Wu J.T, Joseph-Ridge N, Vernillet L, Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects, British Journal of Clinical Pharmacology, 2008; 65(3): 355-363.
10. Love B.L, Barrons R, Veverka A, Snider K.M. Urate-lowering therapy for gout: focus on febuxostat. Pharmacotherapy.2010; 30:594-608.